Clinical Trial

Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 24, 2025 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-30.
Trial Details
NCT Number NCT06912295
Lead Sponsor Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Conditions Healthy Participants
Enrollment 76 participants
Start Date 2025-03-21
Primary Completion 2025-08-30 (estimated)
Study Completion 2025-10-09 (estimated)
Updated on ClinicalTrials.gov 2025-08-24